Michael Ulz
Stock Analyst at Baird
(4.71)
# 199
Out of 5,182 analysts
107
Total ratings
63.64%
Success rate
32.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $21 → $15 | $8.00 | +87.50% | 9 | Mar 25, 2026 | |
| CABA Cabaletta Bio | Maintains: Overweight | $14 → $13 | $3.13 | +315.34% | 7 | Mar 24, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $18.68 | +151.61% | 4 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Equal-Weight | $29 → $7 | $3.94 | +77.66% | 2 | Mar 2, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.46 | +334.78% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $95.20 | +29.20% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $322.11 | +26.66% | 13 | Jan 30, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $65.14 | +24.35% | 7 | Jan 7, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.95 | +179.33% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $75.17 | +25.05% | 8 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $98 → $102 | $34.26 | +197.72% | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $5.73 | +336.30% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.70 | +440.54% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.24 | +464.52% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.15 | +166.01% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.87 | +2,191.21% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.49 | +1,189.40% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $140 | $8.51 | +1,545.12% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.49 | -33.18% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.50 | +215.79% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $23.30 | +243.35% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.46 | +3.73% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $21 → $15
Current: $8.00
Upside: +87.50%
Cabaletta Bio
Mar 24, 2026
Maintains: Overweight
Price Target: $14 → $13
Current: $3.13
Upside: +315.34%
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $18.68
Upside: +151.61%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Equal-Weight
Price Target: $29 → $7
Current: $3.94
Upside: +77.66%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.46
Upside: +334.78%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $95.20
Upside: +29.20%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $322.11
Upside: +26.66%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $65.14
Upside: +24.35%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.95
Upside: +179.33%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $75.17
Upside: +25.05%
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $34.26
Upside: +197.72%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.73
Upside: +336.30%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.70
Upside: +440.54%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.24
Upside: +464.52%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.15
Upside: +166.01%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.87
Upside: +2,191.21%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.49
Upside: +1,189.40%
Jan 27, 2023
Maintains: Overweight
Price Target: $280 → $140
Current: $8.51
Upside: +1,545.12%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.49
Upside: -33.18%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.50
Upside: +215.79%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $23.30
Upside: +243.35%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.46
Upside: +3.73%